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Background: There is no established noninvasive or invasive diagnostic imaging modality at present that can serve
as a ‘gold standard’ or “benchmark” for the detection of the venous anomalies, indicative of chronic cerebrospinal
venous insufficiency (CCSVI). We investigated the sensitivity and specificity of 2 invasive vs. 2 noninvasive imaging
techniques for the detection of extracranial venous anomalies in the internal jugular veins (IJVs) and azygos
vein/vertebral veins (VVs) in patients with multiple sclerosis (MS).
Methods: The data for this multimodal imaging comparison pilot study was collected in phase 2 of the
“Prospective Randomized Endovascular therapy in Multiple Sclerosis” (PREMiSe) study using standardized imaging
techniques. Thirty MS subjects were screened initially with Doppler sonography (DS), out of which 10 did not fulfill
noninvasive screening procedure requirements on DS that consisted of ≥2 venous hemodynamic extracranial
criteria. Accordingly, 20 MS patients with relapsing MS were enrolled into the multimodal diagnostic imaging study.
For magnetic resonance venography (MRV), IJVs abnormal findings were considered absent or pinpoint flow,
whereas abnormal VVs flow was classified as absent. Abnormalities of the VVs were determined only using
non-invasive testing. Catheter venography (CV) was considered abnormal when ≥50% lumen restriction was
detected, while intravascular ultrasound (IVUS) was considered abnormal when ≥50% restriction of the lumen or
intra-luminal defects or reduced pulsatility was found. Non-invasive and invasive imaging modality comparisons
between left, right and total IJVs and between the VVs and azygos vein were performed. Because there is no
reliable way of non-invasively assessing the azygos vein, the VVs abnormalities detected by the non-invasive testing
were compared to the azygos abnormalities detected by the invasive testing. All image modalities were analyzed in
a blinded manner by more than one viewer, upon which consensus was reached. The sensitivity and specificity
were calculated using contingency tables denoting the presence or absence of vein-specific abnormality findings
between all imaging modalities used individually as the benchmark.
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Results: The sensitivity of CV + IVUS was 68.4% for the right and 90% for the left IJV and 85.7% for the azygos
vein/VVs, compared to venous anomalies detected on DS. Compared to the venous anomalies detected on MRV,
the sensitivity of CV + IVUS was 71.4% in right and 100% in left IJVs and 100% in the azygos vein/VVs; however, the
specificity was 38.5%, 38.9% and 11.8%, respectively. The sensitivity between the two invasive imaging techniques,
used as benchmarks, ranged from 72.7% for the right IJV to 90% for the azygos vein but the IVUS showed a higher
rate of venous anomalies than the CV. There was excellent correspondence between identifying collateral veins on
MRV and CV.
Conclusions: Noninvasive DS screening for the detection of venous anomalies indicative of CCSVI may be a reliable
approach for identifying patients eligible for further multimodal invasive imaging testing of the IJVs. However, the
noninvasive screening methods were inadequate to depict the total amount of azygos vein/VVs anomalies
identified with invasive testing. This pilot study, with limited sample size, shows that both a non-invasive and
invasive multimodal imaging diagnostic approach should be recommended to depict a range of extracranial
venous anomalies indicative of CCSVI. However, lack of invasive testing on the study subjects whose results were
negative on the DS screening and of healthy controls, limits further generalizibility of our findings. In addition, the
findings from the 2 invasive techniques confirmed the existence of severe extracranial venous anomalies that
significantly impaired normal blood outflow from the brain in this group of MS patients.
Keywords: Chronic cerebrospinal venous insufficiency (CCSVI), Multiple sclerosis, Multimodal imaging, Doppler
sonography, Magnetic resonance venography, Catheter venography, Intravascular ultrasound, Extracranial venous
anomaliesBackground
In 2009, Zamboni et al. described a vascular condition in
patients with multiple sclerosis (MS) named chronic cere-
brospinal venous insufficiency (CCSVI), as a restriction of
main extracranial cerebrospinal venous routes that is
caused by anomalies, which interfere with normal intra-
cranial venous outflow [1,2].
CCSVI implies a pathological condition for which non-
invasive diagnosis is based mainly on the detection of ≥2
positive venous hemodynamic (VH) criteria on color Dop-
pler sonography (DS) in the extracranial (neck) and intra-
cranial veins by assessing 5 proposed VH criteria [1,2].
The non-invasive DS diagnosis of CCSVI has been origin-
ally confirmed by the use of invasive catheter venography
(CV) examination [1,3]. On CV, extracranial pathology
was considered significant if the stenosis detected by ven-
ous diameter reduction was equal to or exceeded 50% in
any of the internal jugular veins (IJVs) or the azygos vein
[1]. Because of the advantages of the DS being noninvasive
and providing high-resolution images with real time dy-
namic information of functional and structural venous
anomalies at a relatively low cost, it has been promoted as
a method of choice for the screening of CCSVI [4].
However, subsequent studies showed that the reprodu-
cibility of DS VH criteria depends on the training and
skills of the operator and that they are not easily blinded
or standardized in either research or clinical settings [5-8].
Moreover, the pathologic value of the CCSVI diagnosis by
DS is controversial because the categorical construct of
the CCSVI diagnosis (≥2 and <2 VH DS criteria fulfilled)most likely contributed to explaining major inconsisten-
cies in the prevalence of findings of CCSVI between differ-
ent studies in MS ranging from 0-100% [1,5,9-17]. In
addition, CCSVI is not specific for MS, as it was described
in a substantial number of healthy controls and patients
with other neurological diseases [5,10,18].
At this time, there is no established noninvasive or in-
vasive diagnostic imaging modality that can serve as a
“gold standard/benchmark” for the detection of extracra-
nial venous anomalies, indicative of CCSVI. Each pro-
posed imaging modality for the screening and diagnosis
of CCSVI has its own advantages and disadvantages
[19]. Therefore, most likely, only a multimodal imaging
approach will represent the most comprehensive means
for the screening, diagnosis as well as monitoring for
these extracranial venous anomalies.
Against this background,the goal of this study was to
define and reliably detect extracranial venous anomalies,
indicative of CCSVI in the IJVs and azygos vein/vertebral
veins (VVs) of patients with MS. We investigated the
sensitivity and specificity of 2 invasive vs. 2 noninvasive




Prospective Randomized Endovascular Therapy in Multiple
Sclerosis (PREMiSe; ClinicalTrials.gov. NCT01450072) is
an endovascular angioplasty pilot study, planned in two
phases, which included 30 patients with MS. Phase I was an
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CCSVI, whereas phase 2 was sham-controlled, randomized,
double-blind and included 20 patients. Patients obtained
their baseline diagnostic assessment between June of 2010
and March of 2012. Phase 1 was planned to optimize work
flow, standardize protocols and blinding methodologies
for Phase 2 with the use of invasive imaging techniques
(CV and IVUS) for a more accurate extracranial venous
drainage assessment and venous angioplasty; hence, the im-
aging protocols were not performed in a standardized fash-
ion. Therefore, the present study describes baseline
diagnostic multimodal standardized imaging assessments
limited to patients included in Phase 2. The study was ap-
proved by the Institutional Review Board of the University
at Buffalo and was overseen by an independent data-safety
monitoring committee. All participants gave their written
informed consent.
Inclusion criteria for phase 2 of the PREMiSe study at
screening were as follows: 1) age 18–65 years; 2) active-
relapsing MS defined as having one relapse within the past
12 months; or 3) presence of gadolinium-enhancing lesion
(s) on post-contrast MRI within the previous 3 months; 4)
being on concomitant disease-modifying treatments exclud-
ing natalizumab; 5) having relapsing MS, [20] ExpandedFigure 1 Doppler sonography venous hemodynamic (VH) criteria for
A. VH criteria 1 - Reflux or bidirectional flow noted in the internal jugular v
B-mode anomaly and/or stenosis: septum noted in the lower IJV and steno
C. VH criteria 4 - No flow detected in the IJV until the facial vein enters IJV,
No flow in vertebral veins (VV) despite low wall filter and low velocity scale
in the upright position than in the supine position resulting in a negative dDisability Status Scale (EDSS) [21] of 0–5.5; and 6) ful-
filling ≥2 CCSVI VH extracranial DS criteria [1].
Exclusion criteria for the PREMiSe study at screening
were: an acute relapse, disease progression and/or steroid
treatment within 30 days preceding study entry, pre-
existing medical conditions known to be associated with
brain pathology (e.g., neurodegenerative disorder, cerebro-
vascular disease, positive history of alcohol abuse), severe
peripheral chronic venous insufficiency, severe contrast
media allergy (anaphylaxis) and abnormal renal function.
Doppler sonography
Patients needed to fulfill noninvasive DS extracranial VH
criteria, [1] to qualify for the invasive diagnostic part of
the study. DS examination was performed using a color-
coded scanner (MyLab Gold 25; Esaote-Biosound, Irvine,
California) equipped with a 7 to 10-Mhz transducer to
examine IJVs and vertebral veins (VVs) morphology as
well as hemodynamics. The detailed scanning protocol
and validation were previously reported [5,6,8]. Briefly, the
following 5 VH parameters indicative of CCSVI were in-
vestigated (Figure 1): 1) Reflux/bidirectional flow in the
IJVs and/or in the VVs in the sitting and supine positions,
defined as flow directed towards the brain for a durationdiagnosis of chronic cerebrospinal venous insufficiency (CCSVI).
ein (IJV) with the head in supine and upright position, B. VH criteria 3 -
sis noted in the left IJV with a cross sectional area (CSA) ≤0.3 cm2;
IJV demonstrates no flow above facial vein entry; D. VH criteria 4 -
; E. VH criteria 5 - Negative delta CSA – IJV cross sectional area is larger
elta CSA (supine IJV CSA 11.54 – upright IJV CSA 12.90 = −1.36 mm).
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veins defined as “reverse flow” for a duration of 0.5 s in
one of the intra-cranial veins; 3) B-mode abnormalities or
stenosis in IJVs. IJV stenosis was defined as a cross-
sectional area (CSA) ≤0.3 cm2; 4) Flow that is not Doppler-
detectable in IJVs and/or VVs despite multiple deep
breaths and 5) Reverted postural control of the main cere-
bral venous outflow pathway by measuring the difference
in the CSA in the IJVs in the supine and upright positions.
A subject was considered positive at screening in phase 2
if ≥2 VH extracranial criteria (1, 3, 4, and 5) were fulfilled.
Magnetic resonance venography
All subjects were examined on a 3 T GE Signa Excite HD
12.0 scanner (General Electric, Milwaukee, WI). A multi-
channel head and neck (HDNV) coil was used to acquire
the following sequences: an unenhanced 2D-Time of Flight
(TOF) and enhanced 3D-Time Resolved Imaging of Con-
trast KineticS (TRICKS), as previously described [6,8,22-24].
The parameters used for TOF were: TR/TE 17/4.3 msec
(repetition/echo time), flip angle of 70 degrees, 1.5 mm slice
thickness, field of view (FOV) = 220 mm, acquisition matrix
320/192, phase FOV 75%, for an in-plane resolution (IPR) of
0.7 mm × 1.1 mm and acquisition in axial scan plane. The
parameters used for TRICKS were: TR/TE 4.2/1.6 msec, flip
angle of 30 degrees, 2 mm slice thickness, FOV= 340 mm,
acquisition matrix 320/192, phase FOV 75%, IPR= 1.1 mm ×
1.8 mm and acquisition in coronal scan plane. Intravenous
gadolinium contrast (Omniscan®, GE Healthcare, Princeton
NJ) was injected at a rate of 2 ml/s using a pressure injector
followed by a 20 ml saline flush. The total volume of con-
trast was 20 ml. After acquisition of a 12 second mask (pre-
contrast phase), the scanning of subsequent phases began
simultaneously with the intravenous injection. The scan
protocol consisted of 18 phases of acquisition, each of aFigure 2 Example of normal and abnormal flow morphology in intern
(3D TRICKS and axial 2D TOF). Normal (A & B) flow morphology in both
jugular vein (arrow) with prominent collateral veins (dotted arrows).5 second duration. The flow morphology, indicative of ana-
tomical stenoses, of IJVs was assessed on axial source TOF
images, as well as on axial reconstructed TRICKS images, as
previously described [22]. The IJV flow was evaluated on
an ordinal scale ranging from absent (no visible flow) to
ellipsoidal (patent lumen) and defined in 5 qualitative
flow categories: absent, pinpoint, flattened, crescentic
and ellipsoidal. Only absent or pinpoint flow of the IJVs
was considered to be abnormal (Figure 2), while the
flow of the VVs was classified as absent/present.
In this study, we also assessed the presence and number
of collateral veins, as previously described [22]. These in-
cluded anterior and external jugular veins, facial veins, thy-
roid veins as well as deep cervical veins (Figure 2).
Catheter venography
The detailed protocol of the diagnostic CV was recently
reported [25]. Under conscious sedation using local
anesthesia, an 8-French sheath was inserted using a
modified Seldinger technique into the common femoral
vein. Through this sheath, a guide catheter (5-French,
90-cm-long Head Hunter, Terumo Europe, Leuven, Belgium)
was advanced through the inferior vena cava, across the
right atrium into the superior vena cava. Catheterization
proceeded to the azygos vein outlet into the superior vena
cava. With the help of a hydrophilic guide wire (0.035-inch
diameter Radiofocus Guide Wire M, Terumo Europe), the
catheter was advanced inside the azygos vein until it
neared the confluence with the hemi-azygos vein at the
level of the diaphragm. An autoinjector was used to instill
9 ml of contrast medium (Visipaque, iodixanol, GE
HealthCare; 270 mg/mL) at a constant rate of 3 ml/sec.
Subtraction digital CV of the azygos vein was completed,
with a right posterior oblique projection (range, 15°-25°)
and an extended recording time. In this way, it wasal jugular vein (IJV) on magnetic resonance venography
IJV (arrows). Abnormal (absent flow) (C & D) flow in the left internal
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origin of the azygos vein and hemi-azygos veins up to the
ascending lumbar veins. Subsequently, the right IJV and
left IJV were approached, in that order. With the help of
the guide wire, the catheter was moved inside each IJV up
to the junction with the jugular bulb (skull base). Contrast
medium (12 ml) was injected at a constant rate of 3 ml/sec.
Subtraction digital CV of each IJV was completed with
an anterior-posterior projection and an extended recor-
ding time. Significant stenosis was considered to be any
venous lumen diameter reduction ≥50% (Figure 3).
Collateral draining veins during IJV injection were
classified to either epidural plexus or other collaterals
(mainly anterior and external jugular veins, not along
the spinal cord). Azygos vein collaterals were classified
as either epidural (spinal) or other collaterals.
Intravascular ultrasound
The detailed protocol of the diagnostic IVUS was re-
cently reported. [25] IVUS (Eagle Eye platinum cath-
eter −20 MHz probe; Volcano s5/s5i Imaging system;
Volcano, San-Diego, CA) was consistently performed,
independent of the stenosis, to identify venous anom-
alies. Significant stenosis was considered to be any
venous lumen diameter reduction ≥50% (Figure 4) and
was calculated as the ratio between the minimal diam-
eter of the vein in any of the axial images and the max-
imal diameter of the vein in any of the images. All
identified stenoses were confirmed to be structural and
not physiological by asking the patient to perform a
Valsalva maneuver during the IVUS study.
Additional abnormal predefined IVUS abnormalities in-
cluded the presence of various intra-luminal defects includ-
ing webs, fibrotic annulus-like constrictions, flaps, septa
and vein divided into multiple channels, intra-luminal
hyperechoic filling defect (IHFD) and double parallel lumen
(DPL). IVUS scans were also interpreted for reduced re-
spiratory pulsatility or normal pulsatility (presence or ab-
sence of expansion movements of the vein wall according
to respiratory excursions [10-20/min]).Figure 3 Catheter venography of azygos and internal jugular veins (I
internal jugular vein (IJV) (B). Significant stenosis of the distal left IJV (C) wiMultimodal imaging comparisons
Non-invasive and invasive imaging modality compari-
sons were performed between the left, right and total
IJVs and between the VVs and azygos vein. The criteria
for the comparison of noninvasive and invasive findings
are shown in Table 1. Figure 5 shows a comparison be-
tween 2 noninvasive and 2 invasive imaging techniques.
For DS, IJV abnormal findings were positive for VH DS
criteria 1, 3, 4 and 5. According to this classification, the
presence of at least one of the following IJV DS anomalies
were considered an abnormal IJV exam: reflux/bidirec-
tional flow in sitting and supine positions, presence of B-
mode abnormality (web, flap, membrane, malformed valve,
septum), stenosis ≤0.3 cm2, absence of detectable flow and
negative ΔCSA. Similar criteria were developed to deter-
mine VV DS abnormal findings. Positive VH criteria 1 and
4 (reflux/bidirectional flow and absence of detectable flow)
were considered abnormal VV exams for DS. For MRV,
IJV absent or pinpoint flow were considered abnormal
findings. Abnormal flow of the VVs was classified as ab-
sent. Abnormalities of the VVs were determined only by
using non-invasive testing. The azygos vein was not inves-
tigated by DS or MRV.
Abnormal findings on CV for IJVs and azygos vein
were considered to have the presence of significant sten-
osis. IVUS IJVs and azygos vein abnormalities included
the presence of stenosis, intra-luminal abnormality or
reduced respiratory pulsatility.
Because there is no reliable way of non-invasively as-
sessing the azygos vein, the VVs abnormalities detected by
the non-invasive testing were compared to the azygos ab-
normalities detected by the invasive testing.
Blinding, training and reading of the multimodal exams
The DS was performed by 2 trained technologists (KM
and VV) with previously reported test-retest reproducibil-
ity [5,6,8]. The CV and IVUS were performed by a single
interventional neurosurgeon/radiologist (AHS) who is very
experienced in the diagnosis of cerebrovascular venous dis-
ease and routinely catheterizes extracranial veins in orderJVs). Example of normal patent lumen of the azygos vein (A) and left
th prominent collateral vein (arrow).
Figure 4 Example of intravascular ultrasound in the internal jugular vein. Normal patent lumen (A) and stenotic lumen (B).
Zivadinov et al. BMC Neurology 2013, 13:151 Page 6 of 14
http://www.biomedcentral.com/1471-2377/13/151to access intracranial veins. In phase 1 of the PREMiSe
study, he optimized diagnostic workflow and resolved pos-
sible blinding issues on 10 MS subjects with the use of in-
vasive imaging techniques (CV and IVUS) for a more
accurate extracranial venous drainage assessment.
All imaging modalities were analyzed in a blinded man-
ner by more than one viewer, upon which consensus was
reached. All exams were de-identified prior to the reading
so that the double-blinded readers were fully-blinded toTable 1 Multimodal criteria for the detection of abnormal fin
vertebral veins by using 2 noninvasive and 2 invasive imagin
Vein
territory
DS criteria for abnormal
findings
MRV criteria for abnormal
findings
IJVs - VH criteria 1 - presence of
reflux/bidirectional flow in both
sitting and supine positions
- Absent or pinpoint flow on ax
TOF or TRICKS
and/or with or without
- VH criteria 3 - presence of B-
mode abnormalities (web, flap,
membrane, malformed valve,
septum) or CSA ≤0.3 cm2
- presence of collateral veins
(external jugular veins, anterior
jugular veins, facial veins, thyro
veins and deep cervical veins)
and/or
- VH criteria 4 - absence of
detectable flow
and/or
- VH criteria 5- negative CSA
Azygos
vein/ VVs
- VH criteria 1 - presence of
reflux/bidirectional flow in both
sitting and supine positions in
VVs
- Absence of detectable flow in
VVs
and/or
- VH criteria 4 - absence of
detectable flow in VVs
Legend: IJVs - internal jugular veins; VVs - vertebral veins; DS - Doppler sonography
IVUS - intravascular ultrasound; VH - venous hemodynamic criteria; CSA - cross-sectionorigin and the other imaging modalities of the individual
subject exams. Two independent neuroimaging experts
double-read all DS and MRV examinations (KD and DH),
while the CV and IVUS were double-read by two independ-
ent interpreters (AHS and YK). They had access only to the
diagnostic part and not the interventional part of the study.
Additional three expert neuroimaging professionals/neuro-
surgeons/radiologists (RZ, EL and NH) served as a panel to
reach a consensus when there were discrepancies by thedings in the internal jugular veins and in azygos vein/
g techniques
CV criteria for abnormal
findings
IVUS criteria for abnormal
findings
ial - presence of significant stenosis
(defined as venous lumen
reduction ≥50 %)
- presence of significant
stenosis (defined as venous
lumen reduction ≥50 %)
with or without and/or
id
- presence of collateral veins
(either epidural plexus or
anterior and external jugular
veins, not along the spinal cord)
- presence of various intra-




- presence of IHFD and DPL
and/or
- reduced respiratory pulsatility
- presence of significant stenosis
(defined as venous lumen
reduction ≥50 %) in azygos vein
- presence of significant
stenosis (defined as venous
lumen reduction ≥50 %) in
azygos vein
with or without and/or
- presence of collateral veins
(either epidural or other
collaterals)
- presence of various intra-luminal
defects (webs, fibrotic annulus-like
constrictions, flaps, septa, multiple
channels)
and/or
- presence of IHFD and DPL
and/or
- reduced respiratory pulsatility
: MRV - magnetic resonance venography; CV - catheter venography;
al area; IHFD - intra-luminal hyperechoic filling defect; DPL - double parallel lumen.
Figure 5 Multimodal imaging approach of extracranial neck veins. Axial 2D time-of-flight (A), enhanced 3D-time resolved imaging of
contrast kinetics (B & C), intravascular sonography (D), Doppler sonography (E), and catheter venography (F) all showing venous abnormality of
the right internal jugular vein (significant narrowing-arrows) in the same patient.
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reading by a-priori comparing un-blinded reading results of
the individual imaging modalities on a subject level.
Statistical analyses
All analyses were carried out using IBM SPSS Statistics 20
(IBM Corp.). Demographic, clinical and hemodynamic
characteristics were determined by use of frequencies.
Sensitivity, specificity, positive predictive value (PPV)
and negative predictive (NPV) values were calculated using
contingency tables denoting the presence or absence of
vein-specific abnormality findings between all individual
imaging modalities considered as the "gold standard/
benchmark". We also compared combinations of noninva-
sive vs. invasive imaging techniques. Because the inclusion
criteria for the study were the presence of ≥2 VH extracra-
nial criteria, we were able to derive only sensitivity for
comparisons between other imaging techniques and DS.
The odds ratio was reported along with 95% confidence
interval (CI) constructed using the normal approximation.
Results
Table 2 shows the demographic and clinical characteris-
tics of patients participating in the PREMiSe study. In
total, 15 patients signed an informed consent in phase 1and 30 in phase 2 after prescreening qualification proce-
dures were completed. Of those, 5 in phase 1 and 10 in
phase 2 did not fulfill noninvasive screening procedure re-
quirements on DS. Therefore, 10 patients in phase 1 and
20 in phase 2 were enrolled in the invasive screening por-
tion of the PREMiSe study.
All noninvasive and invasive study procedures were
well-tolerated. No intra- or postprocedural complications,
including vessel rupture, thrombosis side effects to the
contrast media or mortality were recorded at 24 hours or
1 month.
Frequency of venous abnormalities on noninvasive and
invasive imaging techniques in phase 2 of the PREMiSe
All 20 patients fulfilled DS screening criteria that showed
anomalies in their IJVs and/or VVs (Figure 1). Of those,
one patient did not fulfill invasive screening criteria for
endovascular intervention (venous lumen diameter reduc-
tion ≥50%).
In particular, 19 (95%) patients showed venous abnor-
mality of the right and 19 (95%) of the left IJV, whereas
there were 7 (35%) patients who showed venous abnor-
mality of the VVs. The MRV venous abnormalities were
found in 7 (35%) of the right and 7 (35%) of the left IJVs
and in 3 (15%) of the VVs (Figure 2). Seventeen (85%)
Table 2 Demographic, clinical and Doppler sonography




Female gender, n (%) 14 (70)
Age in years, mean (SD) median 44.3 (9) 44.6
Age at onset in years, mean (SD) median 33.4 (10) 35.5
Disease duration in years, mean (SD) median 10.9 (7.1) 10
Disease course, n (%)
RR 13 (65)
RP 7 (35)
EDSS, mean (SD) median 3.9 (1.5) 3.8
Type of treatment, n (%)
Interferon beta 15 (75)
Glatiramer acetate 4 (20)
Combination 0 (0)
Others 1 (5)






≥2 CCSVI criteria*, n (%) 20 (100)
≥2 CCSVI extracranial criteria, n (%) 20 (100)
Legend: PREMiSe - Prospective Randomized Endovascular therapy in Multiple
Sclerosis (study); RR - relapsing-remitting; RP - relapsing-progressive;
EDSS - Expanded Disability Status Scale; VH – venous hemodynamic;
CCSVI -chronic cerebrospinal venous insufficiency; SD - standard deviation.
*The overall CCSVI criteria report both the extracranial and intracranial
assessments on DS.
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MRV in the right and 15 (75%) on the left side, both on
TOF and TRICKS. There were a total of 2.3 (SD 1.2, range
0–4) collateral neck veins on TOF and 2.3 (SD 1.2, range
0–4) on TRICKS.
Eleven (55%) patients showed venous abnormality on
CV of the right IJV, 14 (73.6%) of the left IJV and 10
(50%) of the azygos veins (Figure 3). Of all stenotic le-
sions detected by CV in the right IJVs, 11 (100%) were
in the lower segment (J3) and 3 (30%) were in the upper
segment (J1 or J2), whereas in the left IJVs, 11 (78.6%) of
the 14 stenotic veins had lesions detected in the lower
segment (J3) and 10 (76.9%) in the upper segment (J1 or
J2). The stenotic segment in the azygos vein was in the
same location (descending part of the azygos vein distal
to the azygos arch). Two of the 20 (10%) left IJVs were
not examined by IVUS and one (10%) by CV because of
the difficulty to access with the wire. Only 13 of the 14
cases who showed venous abnormality in the left IJVwere considered for comparison between CV and IVUS, as
one case overlapped with one of the 2 cases who did not get
examined with IVUS. Epidural collateral veins were found in
14 (70%) right and 16 (88.9%) left IJVs and in 16 (80%) of
the azygos veins. Other collaterals were less common.
In total, 10 (50%) right and 15 (83.3%) left IJVs and 17
(85%) azygos veins, demonstrated an IVUS abnormality
(Figure 4). The stenosis on IVUS was detected in 7 (35%)
right and 11 (61%) left IJVs and in 8 (40%) azygos veins.
Reduced respiratory pulsatility was observed in 7 (35%)
right and 10 (55.5%) left IJVs and in 7 (35%) azygos veins.
Intraluminal abnormalities (septa, vein divided into mul-
tiple channels, IHFD and DPL) were detected in all vessels.
Sensitivity and specificity analyses between noninvasive
and invasive venous abnormality findings in phase 2 of
the PREMiSe study
Table 3 shows sensitivity analyses of noninvasive and inva-
sive imaging techniques vs. DS (as a "gold standard/bench-
mark") for the detection of abnormal findings in the IJVs
and in azygos vein/VVs. The sensitivity of CV + IVUS was
68.4% for the right and 100% for the left IJV, compared to
venous anomalies detected on DS. The sensitivity of IVUS
to detect venous anomalies in azygos vein/VVs was high
when compared to DS (85.7%).
Table 4 shows the sensitivity, specificity, PPV, NPV and
OR of noninvasive and invasive imaging techniques vs.
MRV as the "gold standard/benchmark" for the detection
of abnormal findings in the IJVs and in azygos vein/VVs.
Compared to the venous anomalies detected on MRV, the
sensitivity for the detection of venous abnormalities on
CV + IVUS was 71.4% in the right and 100% in left IJVs
and 100% in azygos but the specificity was 38.5%, 38.9%
and 11.8%, respectively.
The sensitivity, specificity, PPV, NPV and OR of IVUS vs.
CV as the "gold standard/benchmark" for the detection of
abnormal findings in the IJVs and in azygos vein/VVs is
shown in Table 5. The sensitivity of IVUS ranged from
72.7% for right IJV to 90% for the azygos vein, although the
IVUS showed a higher rate of venous anomalies than CV.
Table 6 shows the sensitivity, specificity, PPV, NPV and
OR of invasive imaging techniques vs. DS +MRV com-
bined as the "gold standard/benchmark" for the detection
of abnormal findings in the IJVs and in azygos vein/VVs.
Again, because the inclusion criteria for the study were
having a presence of ≥2 VH extracranial criteria, we were
able to derive only sensitivity findings. The sensitivity for
the detection of venous anomalies using invasive imaging
techniques did not increase compared to DS +MRV.
Discussion
This is the first multimodal imaging study in which 2
noninvasive and 2 invasive diagnostic techniques for the
detection of extracranial venous anomalies, indicative of
Table 3 Comparison of Doppler sonography (as "gold
standard/benchmark") for the detection of abnormal
findings in the internal jugular veins and in azygos vein/


















IJV right 19 20 MRV IJV right 7 20 36.8
CV IJV right 11 57.9
IVUS IJV right 10 52.6
CV + IVUS IJV
right
13 68.4
IJV left 19 19 MRV IJV left 7 20 36.8
CV IJV left 14 19 73.7
IVUS IJV left 15 18 83.3
CV + IVUS IJV left 18 18 NA*
IJVs total 20 20 MRV IJV total 8 20 40
CV IJV total 17 85
IVUS IJV total 18 90
CV + IVUS IJV
total
20 NA*
VVs total 7 20 MRV VV total 3 20 28.6







Legend: IJV(s) - internal jugular vein(s); VVs - vertebral veins; MRV - magnetic
resonance venography; CV - catheter venography;
IVUS - intravascular ultrasound.
Nineteen and18 patients successfully obtained CV and IVUS in the left IJV,
respectively (because of difficulty to access with the wire). All 20 patients
successfully obtained other noninvasive and invasive examinations in the
explored vein territories. Therefore, for the left IJVs comparisons with CV and
IVUS, only data from 19 and 18 patients were used.
*The SPSS does not provide an estimate of odds ratio or its confidence
interval whenever there is a zero count in the contingency table. Instead, it
returns an estimate of relative risk. Therefore those results are reported as
"not available".
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http://www.biomedcentral.com/1471-2377/13/151CCSVI were applied. The main finding of the study is
that invasive techniques confirmed that noninvasive DS
screening was a reliable approach for identifying patients
eligible for further multimodal invasive imaging testing
of the IJVs. In 19 of the 20 MS patients, the extracranial
venous IJV anomalies indicative of CCSVI diagnosis
were confirmed on CV or IVUS. However, it has to be
noted that 50% of the screened MS population did not
fulfill ≥2 extracranial VH DS criteria and were therefore
not eligible to undergo invasive testing, which limited
the study ability to investigate specificity of DS vs. inva-
sive imaging diagnostic techniques. Nevertheless, the
findings from this multimodal study are important, as
they suggests that DS can be used reliably to select thosepatients who may present extracranial IJV venous anomal-
ies, indicative of CCSVI, while in the same time, it can po-
tentially exclude those patients who should not undergo an
invasive testing of the IJVs. However, the noninvasive
screening methods were inadequate to depict the total
amount of VV anomalies that would indirectly reflect the
pathology of the azygos vein identified with invasive test-
ing. These findings are related to the fact that we were not
able to directly non-invasively assess the azygos vein. In
our opinion and experience [6,8,22,23], there are no reli-
able, non-invasive imaging modalities at this time that
would directly image the azygous vein in vivo. Another im-
portant finding is related to the results from the invasive
portion of the study, which confirmed the existence of se-
vere extracranial venous anomalies, indicative of CCSVI
that significantly impaired blood outflow from the brain.
A growing body of evidence suggests that the majority
of CCSVI pathology is confined to the intra-luminal por-
tion of extracranial veins, which requires high-resolution
DS or IVUS B-mode imaging for the visualization of
these anomalies [8,26,27]. It has been shown that the
presence and number of these anomalies may contribute
to a higher number of collateral neck veins and func-
tional abnormalities [8,27]. While CV is considered to
be "the gold standard - benchmark" for detecting sten-
osis in blood vessels associated with altered blood flow,
the PREMiSe study showed that CV may not be sensitive
enough to reveal the exact nature of narrowed vein seg-
ments [25]. CV is a luminogram and brings little or no
data regarding the vessel's intra-luminal structures be-
cause of dense opacification of the lumen with contrast,
which obliterates subtle intra-luminal structures [19].
There are no consensus guidelines with respect to the use of
angiographic contrast for extrcranial CV examination [28].
The recent position statement of the International Society
for Neurovascular Disease on the use of angiographic con-
trast for the assessment of IJVs and the azygos vein on CV
does not provide clear guidelines on this issue [29]. Angio-
graphic contrast may be used diluted (1:1) or non-diluted.
While the diluted contrast may allow a better visualization
of endoluminal structures (valve leaflets, webs, etc.) non-
diluted contrast allows a better opacification of epidural and
other collaterals, as well as a better estimation of overall fea-
tures of the veins [28]. In the PREMiSe study, non-diluted
contrast was used. It could be that use of a diluted contrast
could have produced different findings. The PREMiSe study
also demonstrated the advantage of IVUS compared to CV
in detecting intra-luminal abnormalities as well as the im-
portance of including IVUS during CV examination, espe-
cially for the assessment of the azygos vein [25]. It is
important to note that sensitivity of IVUS to depict extracra-
nial venous anomalies on DS, indicative of CCSVI, was in
better agreement than the CV findings, especially for the
azygos vein/VVs territory. However, one of the important
Table 4 Comparison of magnetic resonance venography (as "gold standard-benchmark") for the detection of abnormal findings in the internal jugular veins
and in azygos vein/vertebral veins using other noninvasive and invasive imaging techniques
MRV # of positive cases Noninvasive and invasive imaging modalities # of positive cases Total # of cases Sensitivity Specificity PPV NPV OR
IJV right 7 CV IJV right 11 20 35 53.8 45.5 77.8 2.92 (.41-20.89)
IVUS IJV right 10 71.4 34.8 25 80 4 (.55-29.09)
CV + IVUS IJV right 13 71.4 38.5 38.5 71.4 1.56 (.22-11.37)
IJV left 7 CV IJV left 14 19 57.1 23.1 28.6 50 .40 (.06-2.89)
IVUS IJV left 15 18 100 27.3 46.7 100 1.88 (1.17-3.01)
CV + IVUS IJV left 18 18 NA* NA* NA* NA* NA*
IJVs total 8 CV IJV total 17 20 75 8.3 35.3 33.3 .27 (.02-3.67)
IVUS IJV total 18 100 16.7 44.4 100 1.8 (1.19-2.72)
CV + IVUS IJV total 20 100 0 0.4 — —
VVs total 3 CV azygos total 10 20 0 41.2 0 70 .7 (.47-1.05)
IVUS azygos total 17 100 17.6 17.6 100 1.21 (.97-1.51)
CV + IVUS azygos total 18 100 11.8 16.7 100 1.20 (.98-1.48)
Legend: MRV - magnetic resonance venography; IJVs - internal jugular veins; VVs - vertebral veins; DS - Doppler sonography: MRV - magnetic resonance venography; CV - catheter venography;
IVUS - intravascular ultrasound; OR - odds ratio.
Nineteen and 18 patients successfully obtained CV and IVUS in the left IJV, respectively (because of difficulty to access with the wire). All 20 patients successfully obtained other noninvasive and invasive examinations
in the explored vein territories. Therefore, for the left IJVs comparisons with CV and IVUS, only data from 19 and 18 patients were used.
*The SPSS does not provide an estimate of odds ratio or its confidence interval whenever there is a zero count in the contingency table. Instead, it returns an estimate of relative risk.


















Table 5 Comparison of catheter venography (as "gold standard/benchmark") for the detection of abnormal findings in











Sensitivity Specificity PPV NPV OR
IJV right 11 IVUS IJV right 10 20 72.7 77.8 80 70 9.33 (1.19-72.99)
IJV left 13 IVUS IJV left 15 18 84.6 20 73.3 33.3 1.38 (.10-19.64)
IJVs total 17 IVUS IJV total 18 20 88.2 0 83.3 0 1.20 (.98-1.48)
Azygos total 10 IVUS azygos total 17 20 90 20 52.9 66.7 2.25 (.17-29.77)
Legend: IJVs - internal jugular veins; VVs - vertebral veins; D; OR -odds ratio. Nineteen and 18 patients successfully obtained CV and IVUS in the left IJV, respectively
(because of difficulty to access with the wire). All 20 patients successfully obtained other noninvasive and invasive examinations in the explored vein territories.
Therefore, for the left IJVs comparisons with CV and IVUS, only data from 19 and 18 patients were used.
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http://www.biomedcentral.com/1471-2377/13/151limitations of DS screening approach is that the azygos
vein cannot be directly imaged. While the sensitivity for
detecting VV anomalies on IVUS vs. DS was high, DS did
not detect abnormal VV flow in 10 patients who had posi-
tive IVUS in the azygos vein. Similar limitations were ob-
served for MRV. These results suggest that currently,
available noninvasive indirect screening methods are inad-
equate in depicting the total amount of intra-luminal path-
ology of the azygos vein. The sensitivity of CV + IVUS to
define total IJV pathology on DS was 100%. These findings
support results from the 2 previous studies in which a
higher sensitivity of DS to detect extracranial anomalies on
IVUS compared to CV was found in the IJVs [27,30].
These results can also explain findings from some recent
reports that found low correspondence between the DS
screening assessment and the CV findings [9,31].Table 6 Comparison of Doppler sonography and magnetic re
benchmark") for the detection of abnormal findings in the in
using other invasive imaging techniques
DS +MRV # of positive cases Noninvasive and invasive imaging
IJV right 19 CV IJV right
IVUS IJV right
CV + IVUS IJV right
IJV left 20 CV IJV left
IVUS IJV left
CV + IVUS IJV left
IJVs total 20 CV IJV total
IVUS IJV total
CV + IVUS IJV total
VVs total 8 CV azygos total
IVUS azygos total
CV + IVUS azygos total
Legend: IJV(s) - internal jugular vein(s); VVs - vertebral veins; MRV - magnetic reson
Nineteen and18 patients successfully obtained CV and IVUS in the left IJV, respectiv
obtained other noninvasive and invasive examinations in the explored vein territori
19 and 18 patients were used.
*The SPSS does not provide an estimate of odds ratio or its confidence interval wh
estimate of relative risk. Therefore those results are reported as "not available".Zamboni et al. proposed a set of 5 VH DS criteria by
which MS patients were differentiated from healthy con-
trols with 100% specificity and sensitivity. While the ori-
ginal publication did not provide the exact technical
procedures for the protocol application in either a research
or routine clinical setting, there were recent attempts to
define the standardized CCSVI DS scanning protocol
[5,32,33]. These revised DS protocols propose the use of
quantitative measures for the definition of functional
anomalies such as blood flow velocity and volume that
could be potentially more reliable in assessing the degree
of venous outflow obstruction in the extracranial venous
system [32,33]. They also refine originally proposed VH
criteria [5,32,34] and propose the use of the central blinded
DS reading [33]. In this multimodal comparison of differ-
ent noninvasive and invasive imaging techniques in phasesonance venography (combined as the "gold standard/
ternal jugular veins and in azygos vein/vertebral veins













ance venography; CV - catheter venography; IVUS - intravascular ultrasound.
ely (because of difficulty to access with the wire). All 20 patients successfully
es. Therefore, for the left IJVs comparisons with CV and IVUS, only data from
enever there is a zero count in the contingency table. Instead, it returns an
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http://www.biomedcentral.com/1471-2377/13/1512 of the PREMiSe study, we read findings from multimodal
techniques in a blinded manner by different experts and
using a panel to reach a consensus when there were dis-
crepancies by the readers. They also confirmed the correct-
ness of the exam reading by a-priori comparing un-blinded
reading results of the individual imaging modalities on a
subject level. We did not consider the assessment of the
second CCSVI VH criterion (reflux in deep cerebral veins)
for several reasons: 1) the reproducibility of this criterion is
lower compared to the other 4 VH criteria; [6,7] 2) there is
no direct anatomical extracranial correlate for performing
sensitivity and specificity comparisons with other multi-
modal imaging techniques; 3) use of this criterion contrib-
utes to the highest variability in making a CCSVI diagnosis
and 4) the direction of the blood flow in veins connecting
cortical with deep veins may vary considerably as a conse-
quence of the physiologic inter-individual variation of the
cerebral venous anatomy [11]. Despite this, the results of
the multimodal PREMiSe study further support the value
of DS VH criteria for the screening of extracranial venous
anomalies in territories of left and right IJVs.
When CV + IVUS findings were compared to MRV find-
ings, sensitivity was high but the specificity was low,
confirming our previous results [23,24]. Some other inves-
tigators used a slightly different grading system for the de-
tection of extracranial venous anomalies on MRV and
found similar sensitivity but better specificity compared to
CV [35]. Therefore, the use of different MRV evaluation
criteria may have yielded different sensitivity and specificity
results compared to CV, IVUS and DS in the PREMiSe
study. While there is still a lack of standardized guidelines
for the detection of extracranial venous anomalies indica-
tive of CCSVI on MRV, the findings from the PREMiSe
study indicate that MRV should be incorporated in the
armentorium of noninvasive screening techniques. Further
work is needed to standardize MRV morphology criteria
[6,22-24,35-37] and incorporate flow and velocity informa-
tion in determining subjects at risk for the detection of ex-
tracranial venous outflow anomalies with hemodynamic
consequences [38-40].
The combination of DS +MRV did not yield better reli-
ability vs. invasive imaging techniques compared to the DS
alone. However, phase 2 of the PREMiSe study included
only MS patients with ≥2 VH extracranial criteria, which
limited our ability to explore the additive value of MRV to
DS in improving sensitivity and specificity vs. other inva-
sive imaging techniques.
It was proposed that extracranial venous collateral circu-
lation is a compensatory mechanism for impaired venous
outflow because it bypasses blocked veins and thereby re-
duces resistance to drainage [6,8,41]. The PREMiSe study
showed an excellent correspondence between identifying
collateral veins on MRV and CV. Approximately, 70%-85%
of patients presented collateral veins on the right and 75%-80% on the left side of IJV on MRV and CV respectively.
In addition, 80% of patients presented with collaterals of
the azygos vein on CV. These findings confirm that the
presence of collaterals on MRV and CV may represent an
indirect compensatory mechanism for impaired venous
outflow. In the previous study, we found high specificity
for distinguishing MS vs. healthy controls based on >1 of
collateral veins in the neck [6].
PREMiSe was an endovascular angioplasty study that did
not include healthy controls or MS patients without the
presence of CCSVI diagnosis on DS. This selection bias of
the included population was an important limitation of this
diagnostic study, as the sensitivity and specificity findings
of noninvasive vs. invasive techniques cannot be general-
ized to the prevalence of findings to other case–control
studies. However, the main aim of this multimodal study
was to define and reliably detect extracranial venous anom-
alies, indicative of CCSVI in the IJVs and azygos vein/VVs
of patients using DS and to confirm the presence of these
anomalies by using 2 invasive imaging techniques. Another
potential limitation of the study is a relatively small sample
size, which could skew our findings. Although PREMiSe
was a limited pilot trial not powered to detect the preva-
lence of CCSVI in the general MS population and healthy
individuals, it confirmed a general prevalence of extracra-
nial venous anomalies, indicative of CCSVI that we have
reported in large cohorts using DS and MRV [5,6,8,22].
Maybe the most important result of the PREMiSe study
is that our multimodal imaging findings contradict the
number of recent DS studies that reported a prevalence of
CCSVI <10% in MS patients [9,11,12,16,17,33,42-44]. In
fact, the invasive diagnostic portion of PREMiSe confirmed
that 19 of the 20 MS patients screened as CCSVI positive
by DS had severe impairment of extracranial venous out-
flow with significant stenosis in the IJVs and azygos veins.
Future, larger, case-controlled, multicenter, multimodal,
noninvasive and invasive imaging studies that will include
healthy controls, MS patients and patients with other
neurological diseases should determine the real prevalence
of CCSVI in these cohorts.
Conclusions
In conclusion, although the use of noninvasive methods
such as DS to confirm the diagnosis of CCSVI presently re-
main controversial, the results from the PREMiSe study in-
dicate that DS is a reliable approach for identifying patients
eligible for further multimodal invasive imaging testing of
the IJVs. However, the noninvasive screening methods
were inadequate to depict the total amount of azygos vein
anomalies identified with invasive testing. This pilot study
of a limited sample size shows that a non-invasive and in-
vasive multimodal imaging diagnostic approach should be
recommended to depict a range of extracranial venous
anomalies indicative of CCSVI. However, a lack of invasive
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http://www.biomedcentral.com/1471-2377/13/151testing on the study subjects whose results were negative
on DS screening and of healthy controls, further limits
generalizibility of our findings. In addition, the findings
from the two invasive techniques confirmed the existence
of severe extracranial venous anomalies that significantly
impaired normal blood outflow from the brain.
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